Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
estimated completion
Principal Investigator
by Robert Bok, MD, PhD (ucsf)
Headshot of Robert Bok
Robert Bok

Description

Summary

This is a single center prospective imaging study investigating the utility of hyperpolarized 13C-pyruvate/metabolic MR imaging. The current protocol will serve as a companion imaging biomarker study paired with standard of care (SOC) therapeutics, as well as investigational therapies that participants may be scheduled to receive outside of this protocol.

Official Title

A Phase I/II Study of Hyperpolarized 13C Pyruvate as a Biomarker of Aggressiveness & Response to Therapy in Patients With Advanced Solid Tumors

Details

PRIMARY OBJECTIVES: Phase I/Part A 1. To optimize the signal-to-noise ratio in detecting intra-tumoral hyperpolarized 13C pyruvate/lactate signal using metabolic MR imaging in participants with advanced solid tumors. Phase II/Part B 1. To determine the mean percent change from baseline in peak intra-tumoral hyperpolarized lactate-to-pyruvate ratio and pyruvate-to-lactate kinetic constant (kPL) after initiation of SOC treatment. SECONDARY OBJECTIVES: Phase I/Part A 1. To further characterize the safety profile of hyperpolarized 13C-pyruvate. 2. To determine the reproducibility of intra-tumoral HP lac/pyr ratio with same-day repeated dose studies. Phase II/Part B 1. To study the association between clinical outcomes and the percent change from baseline in peak intra-tumoral hyperpolarized lactate-to-pyruvate ratio and kPL after initiation of SOC treatment. 2. To further characterize the safety profile of hyperpolarized 13C pyruvate. 3. To determine the reproducibility of intra-tumoral HP lac/pyr ratio with same-day repeated dose studies. OUTLINE: Participants will be enrolled in Part A which is the feasibility, run-in study which includes the iterative adjustment of coil design to optimize imaging parameters within the target tumor lesion(s). If the data from Part A supports further investigation, additional participants will be enrolled in Part B which is a biomarker cohort which includes participants who are planning on being treated with either standard-of-care (SOC) or investigational therapies and will be followed until discontinuation of the treatment regimen outside of this protocol.

Keywords

Advanced Solid Tumor, Biomarker, Neoplasms, Hyperpolarized 13C-Pyruvate, Magnetic Resonance Imaging (MRI)

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Presence of at least one target pelvic, abdominal, thoracic, neck or extremity lesion detected by standard staging scans that, in the judgment of study investigator, would be amenable to hyperpolarized C-13 pyruvate/metabolic MR imaging:
  2. Target lesion must measure at least 1.0 cm in long axis diameter on Computerized tomography (CT) or magnetic resonance imaging (MRI).
  3. The participant is able and willing to comply with study procedures and provide signed and dated informed consent.
  4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  5. Adequate renal function defined as creatinine < 1.5 x upper limit of normal (ULN) or estimated creatinine clearance >50 mL/min (by the Cockcroft Gault equation).
  6. Participants age 18 and older.

Part B only:

  1. Planned treatment for disease with either standard of care regimen or an investigational agent.

You CAN'T join if...

  1. Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent.
  2. Patients with contra- indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips.
  3. Patients with a metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging.
  4. Patients with poorly controlled hypertension, defined as systolic blood pressure at study entry greater than 160mm Hg or diastolic blood pressure greater than 100mm Hg.

Note: The addition of anti-hypertensives to control blood pressure is allowed.

  1. Patients with congestive heart failure or New York Heart Association (NYHA) status >=
  2. Patients who are pregnant or lactating.
  3. A history of clinically significant EKG abnormalities or myocardial infarction (MI) within 6 months of study entry.

Note: Patients with rate-controlled atrial fibrillation/flutter will be allowed on study.

  1. Any condition that, in the opinion of the Principal Investigator,

Location

  • University of California, San Francisco
    San Francisco California 94143 United States

Lead Scientist at University of California Health

  • Robert Bok, MD, PhD (ucsf)
    Robert Bok, MD, PhD, is an Associate Adjunct Professor in the Department of Radiology and Biomedical Imaging and the Hyperpolarized MRI Technology Resource Center at the University of California, San Francisco. Dr. Bok obtained his PhD in Biochemistry from the University of Illinois in 1984, and he earned his MD in Medicine from The Johns Hopkins University, Baltimore in 1989.

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Robert Bok, MD, PhD
ID
NCT05599048
Phase
Phase 1/2 Solid Tumor Research Study
Study Type
Interventional
Participants
Expecting 65 study participants
Last Updated